Companies Cryptocurrencies
Liminal BioSciences Inc
Liminal BioSciences Inc
Exchange: NasdaqGS
IPO Date: 14/10/1994
CEO: Mr. Kenneth Galbraith
Biotechnology Healthcare 🔗
  • LMNL
  • 0.5
  • 15521300
    market cap
  • 0.01010001
If you bought

shares of Liminal BioSciences Inc (LMNL) on
You would have made
Old Price $12 Current Price $12

Liminal BioSciences, Inc. is a biopharmaceutical corporation. The company is headquartered in Laval, Quebec and currently employs 487 full-time employees. The firm is focused on developing a pipeline of small molecule therapeutics to treat patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. The company operates through three segments: Small Molecule Therapeutics Segment, Plasma-derived Therapeutics Segment and Bioseparations segment. The Small Molecule Therapeutics Segment is a small-molecule drug development business. The Plasma-derived Therapeutics Segment includes its plasma-derived therapeutics platform, which enables the development of its pipeline of biopharmaceutical candidates. Bioseparations segment is engaged in bioseparation, specifically for purification of biologics and the elimination of pathogens. Its product candidates include PBI-4050, PBI-4547, Ryplazim IV and Inter Alpha Inhibitor Protein (IAIP).

Address: 440 Armand-Frappier Blvd Bureau 300 Laval QUEBEC H7V 4B4

Stay updated.